company background image
GRIN

Grown Rogue InternationalCNSX:GRIN Stock Report

Market Cap

CA$20.4m

7D

-7.1%

1Y

8.3%

Updated

26 Oct, 2021

Data

Company Financials
GRIN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

GRIN Overview

Grown Rogue International Inc., through its subsidiaries, engages in the cultivation, production, and wholesale of cannabis products in Canada and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Grown Rogue International
Historical stock prices
Current Share PriceCA$0.13
52 Week HighCA$0.10
52 Week LowCA$0.35
Beta0.91
1 Month Change-25.71%
3 Month Change-35.00%
1 Year Change8.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-55.17%

Recent News & Updates

Shareholder Returns

GRINCA PharmaceuticalsCA Market
7D-7.1%-5.7%1.0%
1Y8.3%0.6%36.8%

Return vs Industry: GRIN exceeded the Canadian Pharmaceuticals industry which returned 2% over the past year.

Return vs Market: GRIN underperformed the Canadian Market which returned 36.5% over the past year.

Price Volatility

Is GRIN's price volatile compared to industry and market?
GRIN volatility
GRIN Beta0.91
Industry Beta1.85
Market Beta1

Stable Share Price: GRIN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: GRIN's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aJ. Stricklerhttps://www.grownrogue.com

Grown Rogue International Inc., through its subsidiaries, engages in the cultivation, production, and wholesale of cannabis products in Canada and the United States. The company offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. It sells its products directly to dispensaries.

Grown Rogue International Fundamentals Summary

How do Grown Rogue International's earnings and revenue compare to its market cap?
GRIN fundamental statistics
Market CapUS$16.48m
Earnings (TTM)-US$2.47m
Revenue (TTM)US$6.68m

2.5x

P/S Ratio

-6.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRIN income statement (TTM)
RevenueUS$6.68m
Cost of RevenueUS$3.16m
Gross ProfitUS$3.52m
ExpensesUS$5.99m
Earnings-US$2.47m

Last Reported Earnings

Jul 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.016
Gross Margin52.66%
Net Profit Margin-37.06%
Debt/Equity Ratio26.9%

How did GRIN perform over the long term?

See historical performance and comparison

Valuation

Is Grown Rogue International undervalued compared to its fair value and its price relative to the market?

3.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GRIN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: GRIN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GRIN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GRIN is overvalued based on its PB Ratio (3.3x) compared to the CA Pharmaceuticals industry average (2.4x).


Future Growth

How is Grown Rogue International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

46.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Grown Rogue International performed over the past 5 years?

17.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GRIN is currently unprofitable.

Growing Profit Margin: GRIN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GRIN is unprofitable, but has reduced losses over the past 5 years at a rate of 17.3% per year.

Accelerating Growth: Unable to compare GRIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GRIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).


Return on Equity

High ROE: GRIN has a negative Return on Equity (-37.65%), as it is currently unprofitable.


Financial Health

How is Grown Rogue International's financial position?


Financial Position Analysis

Short Term Liabilities: GRIN's short term assets ($4.6M) exceed its short term liabilities ($2.8M).

Long Term Liabilities: GRIN's short term assets ($4.6M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: GRIN's debt to equity ratio (26.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GRIN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GRIN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GRIN has less than a year of cash runway if free cash flow continues to grow at historical rates of 21.2% each year.


Dividend

What is Grown Rogue International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GRIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GRIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRIN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GRIN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

J. Strickler (41 yo)

2.92yrs

Tenure

US$174,882

Compensation

Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He Co-Founded Grown Rogue International Inc. He is the Director of Grown Rogue Internationa...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD174.88K) is about average for companies of similar size in the Canadian market ($USD164.62K).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GRIN's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: GRIN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GRIN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.9%.


Top Shareholders

Company Information

Grown Rogue International Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Grown Rogue International Inc.
  • Ticker: GRIN
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$20.402m
  • Shares outstanding: 156.94m
  • Website: https://www.grownrogue.com

Location

  • Grown Rogue International Inc.
  • 340 Richmond Street West
  • Toronto
  • Ontario
  • M5V 1X2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:44
End of Day Share Price2021/10/26 00:00
Earnings2021/07/31
Annual Earnings2020/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.